June 28, 2022

BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC)

June 16, 2022

BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer

May 11, 2022

BioLineRx Reports First Quarter 2022 Financial Results and Provides Corporate Update